NCT00955149View on ClinicalTrials.gov

Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Primary Sclerosing CholangitisTrisomy 7CholangiocarcinomaChemoprevention
Interventions
DRUG

Erlotinib (Tarceva)

Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Mayo Clinic

OTHER

NCT00955149 - Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) | Biotech Hunter | Biotech Hunter